Scientific rationale

The IBDTalk 2026 – 3rd edition offers a comprehensive scientific and educational update on the evolving landscape of Ulcerative Colitis (UC). The program bridges current standard care and next-generation therapeutic approaches, addressing key clinical challenges and the multidisciplinary management of complex UC scenarios, including the overlap between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), as well as coexisting Spondyloarthritis (SPA).

The agenda provides a critical review of therapeutic strategies, examining the role of conventional agents (mesalazine, steroids) alongside the timing and real-life effectiveness of advanced therapies, with a specific focus on emerging biological mechanisms. 
Through plenary sessions, tandem talks, the interactive “InflamMaze” workgroups, and the Clinical Case Contest, the event fosters interaction, practical learning, and refinement of clinical decision-making regarding surgical timing, innovative trial designs, and disease management.

Overall, IBDTalk 2026 promotes high-level scientific exchange and fosters innovation, enhancing the adoption of effective clinical approaches and ultimately improving patient outcomes in UC.

UC Clinical talent contest

Invia il tuo caso clinico per condividere esperienze di real life con i tuoi colleghi

Gli autori dei casi clinici selezionati dallo Steering Committee saranno invitati a presentarli al Congresso IBDtalk venerdì 13 marzo 2026. I casi più votati dalla platea riceveranno una premiazione dedicata in sessione plenaria.